6,025 Shares in ResMed Inc. (NYSE:RMD) Acquired by Integrated Investment Consultants LLC

Integrated Investment Consultants LLC acquired a new stake in ResMed Inc. (NYSE:RMD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,025 shares of the medical equipment provider’s stock, valued at approximately $1,378,000.

A number of other institutional investors have also recently bought and sold shares of RMD. True Wealth Design LLC lifted its stake in shares of ResMed by 2,200.0% in the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 110 shares during the period. Ashton Thomas Securities LLC bought a new stake in ResMed in the third quarter valued at about $34,000. Rosenberg Matthew Hamilton acquired a new position in ResMed in the fourth quarter valued at about $54,000. Capital Performance Advisors LLP bought a new position in ResMed during the third quarter worth about $60,000. Finally, Quarry LP grew its position in shares of ResMed by 271.9% during the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 242 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Transactions at ResMed

In other news, insider Justin Leong sold 6,160 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the sale, the insider now owns 21,718 shares in the company, valued at $5,279,428.62. This represents a 22.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total transaction of $491,300.00. Following the completion of the transaction, the director now directly owns 81,218 shares of the company’s stock, valued at $19,951,201.70. This represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,099 shares of company stock worth $2,719,385 in the last three months. Insiders own 0.71% of the company’s stock.

ResMed Stock Up 1.2 %

Shares of ResMed stock opened at $239.89 on Friday. The firm has a market cap of $35.22 billion, a PE ratio of 31.77, a P/E/G ratio of 1.69 and a beta of 0.70. The business’s 50 day simple moving average is $238.51 and its 200 day simple moving average is $232.47. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. ResMed Inc. has a 52-week low of $170.39 and a 52-week high of $260.49.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period last year, the company earned $1.64 earnings per share. The firm’s revenue was up 11.1% compared to the same quarter last year. On average, analysts predict that ResMed Inc. will post 9.36 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th were paid a dividend of $0.53 per share. The ex-dividend date was Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.88%. ResMed’s dividend payout ratio is 28.08%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RMD shares. The Goldman Sachs Group assumed coverage on shares of ResMed in a research note on Thursday. They set a “buy” rating on the stock. Robert W. Baird lifted their price target on shares of ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Bank of America boosted their price target on shares of ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, September 26th. Piper Sandler started coverage on ResMed in a research note on Friday, January 10th. They set a “neutral” rating and a $252.00 price objective on the stock. Finally, Stifel Nicolaus started coverage on ResMed in a report on Friday, December 13th. They issued a “hold” rating and a $250.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $233.09.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.